These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. External application of rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model. Kawatsu S; Oda K; Saiki Y; Tabata Y; Tabayashi K Ann Thorac Surg; 2007 Aug; 84(2):560-7; discussion 567. PubMed ID: 17643635 [TBL] [Abstract][Full Text] [Related]
14. Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts. Zou J; Zhang X; Yang H; Zhu Y; Ma H; Wang S Ann Vasc Surg; 2011 May; 25(4):538-46. PubMed ID: 21549923 [TBL] [Abstract][Full Text] [Related]
15. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts. Schachner T; Oberhuber A; Zou Y; Tzankov A; Ott H; Laufer G; Bonatti J Eur J Cardiothorac Surg; 2005 Feb; 27(2):302-6. PubMed ID: 15691686 [TBL] [Abstract][Full Text] [Related]
16. The new immunosuppressive agent FK778 attenuates neointima formation in an experimental venous bypass graft model. de Graaf R; Kloppenburg G; Tintu A; Rouwet E; Kitslaar P; van Hooff J; Bruggeman C; Stassen F Vascul Pharmacol; 2009; 50(3-4):83-8. PubMed ID: 19010449 [TBL] [Abstract][Full Text] [Related]
17. A Gbetagamma inhibitor reduces intimal hyperplasia in aortocoronary saphenous vein grafts. Petrofski JA; Hata JA; Williams ML; Parsa CJ; Thompson RB; Hanish SI; Gehrig TR; Koch WJ; Milano CA J Thorac Cardiovasc Surg; 2005 Dec; 130(6):1683-90. PubMed ID: 16308016 [TBL] [Abstract][Full Text] [Related]